Abstract

Objectives: Clinical, subclinicalvcharacteristics in diabetic patients after treatment with corticosteroids. Commentary on some relating factors in diabetic patients after corticosteroid treatment. Methods: A cross-sectional descriptive study, 34 patients with a first diagnosis of diabetes and a history of corticosteroid use at the Department of Endocrinology and Diabetes, Rheumatology department, Clinical Immunology Center of Bach Mai Hospital from November 2016 to October 2017. Results: Type of corticosteroid and route of administration: Corticosteroids were used with the highest rate (55.9%); 17.7% using herbs, unknown drugs. 58.8% use GCs intermittently. Taking corticosteroids with systemic admistration appears side effects earlier than local admistration does. Long-term use of high doses of corticosteroids increases the risk of developing diabetes. The time detecting diabetes after treatment of GCs was 54.35 ± 71.37 months. 55.9% of patients had symptoms of hyperglycaemia; 5.9% of patients had hyperthyroidism. Intravenous glucose dose was 20.48 ± 11.51mmol / L and HbA1c: 10.28 ± 2.28%. High doses and extra high doses of corticosteroid often increase the risk of diabetes. Conclusions: Diabetes after GCs treatment is usually diagnosed lately with high intravenous glucose and HbA1c levels and nonspecific clinical symptoms. Systemic GCs causes adverse effects earlier than local glucose, long-term high doses of GCs increases in the risk of developing diabetes.